Historically, dissolution testing parameters could vary between individual product monographs and the general monograph. This led to the Ph. Eur. Commission surveying users in January 2019 regarding three options: retaining a mandatory dissolution test, making it an example, or relying on the general monograph. A compromise was reached in November 2020: a dissolution or disintegration test will be included in each individual product monograph. The specific details and conditions for use are outlined in the of the Ph. Eur.
The , titled Tablets (Compressi) , is a legally binding general monograph that establishes essential quality standards for tablet dosage forms in Europe. As a "general monograph," it provides overarching requirements for production, testing, and labeling that apply to all tablets, unless a specific monograph for a particular drug provides different instructions. Scope and Definition
While the global industry tries to harmonize via the ICH Q4B process, differences remain.
| Category | Description | Key Considerations / Tests | | :--- | :--- | :--- | | | No coating; active substance(s) and excipients are directly exposed. | May be single-layer or multi-layer; must have appropriate mechanical strength to avoid crumbling (tested via friability in 2.9.7 and resistance to crushing in 2.9.8). | | Coated Tablets | Covered with a coating layer to mask taste, protect from the environment, or modify drug release. | Includes film-coated, sugar-coated, and press-coated tablets. | | Effervescent Tablets | Uncoated tablets containing an acid and a carbonate/bicarbonate. They react with water to release carbon dioxide. | Often contain a high quantity of active substances; rapid disintegration is a key feature. | | Soluble Tablets | Uncoated tablets that dissolve completely in water to form a true solution. | Must dissolve completely within a specified time in a specified volume of water. | | Dispersible Tablets | Uncoated tablets that disintegrate in water to form a uniform dispersion, which may be cloudy. | Must meet a specific disintegration test for dispersible tablets. | | Orodispersible Tablets | Designed to be placed in the mouth, where they disintegrate rapidly (e.g., within 3 minutes) before swallowing. | A special type of uncoated tablet. | | Gastro-resistant Tablets | Delayed-release tablets that resist disintegration in gastric fluid but release the active substance in the intestine. | Usually achieved by a coating or by using gastro-resistant granules. | | Modified-release Tablets | Formulated to release the active substance at a specific rate, time, or location (e.g., sustained, prolonged, or controlled release). | Release profile is a key quality attribute; dissolution testing is critical. | | Tablets for Use in the Mouth | Retained in the mouth, where the active substance is liberated. Includes buccal and sublingual tablets. | They must not disintegrate rapidly but must release the active substance slowly. | | Oral Lyophilisates | Solid preparations made by freeze-drying that disintegrate rapidly on the tongue or dissolve/disperse in water before swallowing. | Also known as freeze-dried tablets or Zydis®-type formulations. | European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
To ensure patients receive the intended dose, the break-mark's efficacy must be assessed during product development. The test: break 30 tablets by hand, weigh one part from each, and check mass uniformity. Not more than one part can fall outside 85-115% of the average mass.
This test measures how quickly a tablet breaks down into smaller particles when exposed to a liquid medium (simulating the stomach or intestine).
By understanding and adhering to the standards of Monograph 0478, manufacturers can produce safe, effective, and reliable products that meet the high expectations of regulators and, most importantly, the needs of patients worldwide. Commission surveying users in January 2019 regarding three
Covered with layers of sugars, resins, or polymers.
European Pharmacopoeia (Ph. Eur.) Monograph 0478 establishes essential quality standards for oral tablets, covering classification, uniformity of dosage, and disintegration, with specific requirements for scored tablet functionality. The monograph mandates strict tests for uniformity of content (Chapter 2.9.6) and mass (Chapter 2.9.5), along with specific criteria for break-mark functionality, requiring 85%–115% uniformity for fractional doses. For further detailed technical guidance, professionals can refer to the official EDQM Knowledge Base gmp-compliance.org
Mandatory for tablets with low doses of API (e.g., less than 25 mg or less than 25% of the total mass), requiring individual chemical assays of a specified number of tablets. B. Dissolution (2.9.3) In the pharmaceutical world
Monograph 0478 is a pragmatic framework: not an exhaustive recipe but a regulatory backbone that requires scientific judgment. Manufacturers must interpret it in the context of specific APIs, formulation technologies, and intended clinical use, documenting rationale and validation for any deviations.
In the pharmaceutical world, consistency is everything. For solid oral dosage forms, the is the foundational document that defines what a "tablet" actually is and the rigorous tests it must pass to ensure patient safety and efficacy. What Defines a Tablet under 0478?
Many of the general methods cross-referenced in Monograph 0478 (such as Dissolution 2.9.3 and Uniformity of Dosage Units 2.9.40) have undergone extensive harmonization. This reduces the burden on international manufacturers, allowing them to utilize streamlined testing protocols that satisfy multiple regulatory jurisdictions simultaneously.
The defining characteristic is that the tablet must be homogeneous (dose uniformity) and stable (mechanical resistance to handling).
Monograph 0478 imposes stricter criteria for non-standard tablets.